Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 6/20 | 0.36 |
| ▸ | KDR | P35968 | 6/20 | 0.36 |
| ▸ | HCK | P08631 | 5/20 | 0.36 |
| ▸ | SRC | P12931 | 5/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | TEK | Q02763 | 1/20 | 0.36 |
| ▸ | PFKFB2 | O60825 | 2/20 | 0.35 |
| ▸ | PFKFB1 | P16118 | 2/20 | 0.35 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10097452 | 0.92 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2HPGDMAPTLMNA | |
| SCHEMBL13151831 | 0.91 | SMN1; SMN2 (0.39) | ALDH1A1SMN1; SMN2HPGDMAPTLMNA | |
| SCHEMBL10249891 | 0.91 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2HPGDMAPTKDR | |
| SCHEMBL10250941 | 0.90 | SMN1; SMN2 (0.41) | ALDH1A1SMN1; SMN2HPGDMAPTLMNA | |
| SCHEMBL12950158 | 0.90 | HPGD (0.40) | ALDH1A1SMN1; SMN2HPGDMAPTPFKFB2 | |
| SCHEMBL10249577 | 0.89 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2HPGDMAPTPFKFB2 | |
| SCHEMBL12950083 | 0.89 | SMN1; SMN2 (0.39) | ALDH1A1SMN1; SMN2HPGDMAPTLMNA | |
| SCHEMBL10097675 | 0.88 | SMN1; SMN2 (0.45) | ALDH1A1SMN1; SMN2HPGDMAPTMAPK1 | |
| SCHEMBL13151775 | 0.88 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2MAPTLMNAPFKFB2 | |
| SCHEMBL10096238 | 0.87 | PFKFB2 (0.41) | ALDH1A1SMN1; SMN2HPGDMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | ALDH1A1 1497/4885SMN1; SMN2 3609/4885HPGD 3255/4885 |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | ALDH1A1 1067/4885SMN1; SMN2 4565/4885HPGD 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.